Composition containing hyaluronic acid-crosslinked tropoelastin and method of use thereof
Patent Information
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- アラーガンファーマシューティカルズインターナショナルリミテッド
- Filing Date
- 2026-03-10
- Publication Date
- 2026-06-16
Smart Images
Figure 2026098002000001_ABST
Abstract
Claims
1. A method for treating a soft tissue condition of a subject requiring such treatment, comprising administering a composition comprising tropoelastin crosslinked with hyaluronic acid to the soft tissue of the subject, wherein the composition increases the water content in the soft tissue of the subject compared to a composition in which the tropoelastin is not crosslinked with hyaluronic acid but is otherwise identical.
2. The method according to claim 1, wherein the tropoelastin is crosslinked with the hyaluronic acid without a crosslinking agent.
3. The method according to claim 2, wherein the tropoelastin is crosslinked to the hyaluronic acid via at least one intermolecular crosslinking comprising an amide bond between the amine of the tropoelastin and the carboxyl group of the hyaluronic acid.
4. The method according to claim 1, wherein the tropoelastin comprises human tropoelastin.
5. The method according to claim 1, wherein the tropoelastin comprises recombinant tropoelastin.
6. The method according to claim 1, wherein the tropoelastin comprises recombinant human tropoelastin.
7. The method according to claim 1, wherein the tropoelastin comprises a tropoelastin monomer.
8. The method according to claim 1, wherein the tropoelastin is present in an amount of about 1 mg / ml to about 100 mg / mL.
9. The method according to claim 1, wherein the tropoelastin is present in an amount of about 10 to about 50 mg / mL.
10. The method according to claim 9, wherein the tropoelastin is present in an amount of about 30 mg / mL.
11. The method according to claim 1, wherein the hyaluronic acid is a derivatized hyaluronic acid.
12. The method according to claim 1, wherein the tropoelastin is cross-linked with approximately 0.1% to approximately 5% hyaluronic acid.
13. The method according to claim 12, wherein the tropoelastin is crosslinked with approximately 0.5% hyaluronic acid.
14. The method according to claim 1, wherein the hyaluronic acid is present in an amount of about 1 mg / mL to about 15 mg / mL.
15. The method according to claim 1, wherein the hyaluronic acid is present in an amount of approximately 10 mg / mL or less, approximately 5 mg / mL or less, approximately 4 mg / mL or less, approximately 3 mg / mL or less, approximately 2 mg / mL or less, or approximately 1 mg / mL or less.
16. The method according to claim 1, wherein the tropoelastin:hyaluronic acid ratio is approximately 2:1, approximately 3:1, approximately 4:1, approximately 5:1, approximately 6:1, approximately 7:1, approximately 8:1, approximately 9:1, or approximately 10:
1.
17. The method according to claim 16, wherein the tropoelastin:hyaluronic acid ratio of the composition is about 2:1 or more, and the composition increases the water content in the soft tissue of the subject compared to soft tissue administered with a composition having a tropoelastin:hyaluronic acid ratio less than that of the composition, but otherwise identical.
18. The method according to claim 17, wherein the amount of hyaluronic acid is about 5 mg / mL or less, and the composition increases the water content in the soft tissue of the subject compared to a composition having more than 5 mg / mL of hyaluronic acid but otherwise being the same.
19. The method according to claim 17, wherein the tropoelastin:hyaluronic acid ratio is approximately 6:1 or greater, and the composition increases the water content in the soft tissue of the subject compared to a composition in which the tropoelastin:hyaluronic acid ratio is less than 6:1 but which is otherwise identical.
20. The method according to claim 19, wherein the amount of hyaluronic acid is about 5 mg / mL or less, and the composition increases the water content in the soft tissue of the subject compared to a composition having more than 5 mg / mL of hyaluronic acid but otherwise being the same.
21. The method according to claim 1, wherein the soft tissue is skin.
22. The method according to claim 21, wherein the skin is very dry, dry, or hydrated skin prior to administration of the composition.
23. The method according to claim 22, wherein the skin has a capacitance of less than about 90 a.u., less than about 85 a.u., less than about 80 a.u., less than about 75 a.u., less than about 70 a.u., less than about 65 a.u., less than about 60 a.u., less than about 55 a.u., less than about 50 a.u., less than about 45 a.u., less than about 40 a.u., less than about 35 a.u., less than about 30 a.u., less than about 25 a.u., less than about 20 a.u., less than about 15 a.u., less than 10 a.u., or less than about 5 a.u. before administration of the composition.
24. The method according to claim 21, wherein the soft tissue condition is selected from the group consisting of facial wrinkles, fine wrinkles, thinned skin, aged skin, scar tissue, and skin furrows.
25. The method according to claim 21, wherein the step of administering the composition includes injecting the composition into the skin.
26. The method according to claim 21, wherein the step of administering the composition includes intradermal injection of the composition into the dermis.
27. The method according to claim 21, wherein the step of administering the composition includes injecting the composition into subcutaneous tissue.
28. The method according to claim 21, wherein the step of administering the composition includes subcutaneous injection of the composition.
29. The method according to claim 1, wherein the composition is an injectable composition.
30. The method according to claim 1, wherein the step of administering the composition increases glycosaminoglycan deposition in the tissue.
31. The method according to claim 1, wherein the water content of the soft tissue increases by about 10% to about 80%.
32. The method according to claim 1, wherein the water content of the soft tissue increases by about 20% to about 50%.
33. The method according to claim 1, wherein the water content of the soft tissue increases by about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, or about 50%.
34. A method for increasing the water content in the soft tissues of a subject who requires it, the following: To prepare a subject having soft tissue with a first water content; and A composition containing tropoelastin crosslinked with hyaluronic acid is administered to the soft tissue in an amount effective in generating a second water content in the soft tissue. Includes, The tropoelastin:hyaluronic acid ratio of the aforementioned composition is approximately 2:1 or higher, and The method wherein the second water content is increased compared to soft tissue administered with the composition, having a tropoelastin:hyaluronic acid ratio less than that of the composition, but otherwise identical.
35. The method according to claim 34, wherein the tropoelastin:hyaluronic acid ratio of the composition is about 6:1, and the second water content is increased compared to soft tissue administered with the same composition in all other respects, but with a tropoelastin:hyaluronic acid ratio of less than about 6:
1.
36. The method according to claim 34, wherein the second water content is about 10% to about 80% more than the first water content.
37. The method according to claim 34, wherein the second water content remains greater than the first water content for at least 4 weeks, at least 8 weeks, at least 12 weeks, at least 24 weeks, or at least 48 weeks.
38. The method according to claim 34, wherein the tropoelastin is present in an amount of about 1 mg / ml to about 100 mg / mL.
39. The method according to claim 34, wherein the tropoelastin is cross-linked with approximately 0.1% to approximately 5% hyaluronic acid.
40. The method according to claim 34, wherein the soft tissue is skin.
41. A method for increasing cell infiltration into the soft tissue of a subject in need thereof, comprising administering to the soft tissue of the subject a composition comprising tropoelastin crosslinked to hyaluronic acid, wherein the composition increases cell infiltration into the soft tissue of the subject compared to a composition in which the tropoelastin is not crosslinked to hyaluronic acid but otherwise identical.
42. The method according to claim 41, wherein the method increases the formation of elastin fibers.
43. The method according to any one of claims 41 to 42, wherein the method increases the formation of novel collagen fibers.
44. A method for replenishing the skin of a subject in need, comprising administering a composition comprising tropoelastin crosslinked to hyaluronic acid to the soft tissue or skin of the subject, wherein the composition increases the formation of elastin fibers in the soft tissue or skin of the subject compared to a composition in which the tropoelastin is not crosslinked to hyaluronic acid but is otherwise identical.
45. The method according to claim 44, wherein the method increases the formation of novel collagen fibers.
46. A method for improving the skin composition of a subject requiring such improvement, comprising administering a composition comprising tropoelastin crosslinked to hyaluronic acid to the soft tissue or skin of the subject, wherein the composition increases the formation of elastin fibers in the soft tissue or skin of the subject compared to a composition in which the tropoelastin is not crosslinked to hyaluronic acid but is otherwise identical.
47. The method according to claim 46, wherein the method causes the formation of a novel matrix at the administration site.
48. The method according to claim 46, wherein the method increases the formation of elastin fibers and collagen fibers.
49. The method according to claim 46, wherein the improvement of skin composition includes improving skin brightness.
50. The method according to claim 46, wherein the improvement of skin composition includes improving skin elasticity.
51. The method according to claim 46, wherein the improvement of skin composition includes increasing extracellular matrix proteins at the administration site.